Identitii Limited (ASX:ID8) - Former CFO, Trent Jerome
Former CFO, Trent Jerome
Source : CFIO
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Identitii Limited (ID8) has announced the resignation of its Chief Financial Officer (CFO) Trent Jerome
  • Trent leaves after playing an important role in Identitii’s recent $7.4 million capital raise
  • He has resigned to pursue other opportunities
  • The company is actively searching for a new finance leader to join the team, endeavouring to make the appointment soon
  • Identitii Limited shares are in the grey, trading at 12 cents at 4:50 pm AEDT

Identitii Limited (ID8) has announced the resignation of its Chief Financial Officer (CFO) Trent Jerome.

Trent leaves after overseeing the completion of the company’s FY21 full year results and played an important role in Identitii’s recent $7.4 million capital raise.

He has resigned to pursue other opportunities.

Identitii CEO, John Rayment, says Trent played a key role in the company’s operations.

“We have benefitted immensely from his experience working at other early-stage and listed businesses and he has put financial and operational processes and procedures in place that will help us continue our growth journey,” he said.

The company says it will continue to rely on the finance operational support of Gram Accounting, who have been providing Identitii with virtual CFO services.

Trent’s final day was November 30 and the company is actively searching for a new finance leader to join the team, endeavouring to make the appointment soon.

Identitii Limited shares are in the grey, trading at 12 cents at 4:50 pm AEDT.

ID8 by the numbers
More From The Market Online
The Market Online Video

Market Close: Consumer stocks drag market lower; Alara starts copper production in Oman

The ASX200 has closed the day down 0.15 per cent at 7724 points.
The Market Online Video

Orcoda welcomes Maree Adshead as Non-Executive Director

Orcoda (ASX:ODA) has welcomed Maree Adshead as an independent Non-Executive Director.

Cynata Therapeutics advances Phase 2 trial for high-risk aGvHD treatment

The market has responded favourably to Cynata Therapeutics' announcement regarding its Phase 2 clinical trial on…
The Market Online Video

Market Update: ASX trades flat as materials leads the market

The ASX200 is trading flat this afternoon, up just .10 of a per cent in line…